Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations

Epidemiology

Volumn 25, Issue 6, 2014, Pages 823-828

  Häggström, Christel ^a   Stocks, Tanja ^a,b   Nagel, Gabriele ^c,d   Manjer, Jonas ^e   Bjørge, Tone ^f,g   Hallmans, Göran ^a   Engeland, Anders ^f,g   Ulmer, Hanno ^h   Lindkvist, Björn ^e   Seltner, Randi ^g   Concin, Hans ^d   Tretli, Steinar ⁱ   Jonsson, Håkan ^a   Stattin, Pär ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF ULM   (Germany)

^d AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF BERGEN   (Norway)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ Cancer Registry of Norway   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL; CHOLESTEROL; GLUCOSE BLOOD LEVEL; TUMOR MARKER;

ADULT; ARTICLE; AUSTRIA; BODY MASS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC DISORDER; NORWAY; PRIORITY JOURNAL; PROSTATE CANCER; SMOKING; SWEDEN; SYSTOLIC BLOOD PRESSURE; AGED; ANALYSIS; BLOOD; BLOOD PRESSURE; CAUSE OF DEATH; EPIDEMIOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; PROSTATE TUMOR; QUESTIONNAIRE; REGISTER; RISK FACTOR; SURVIVAL;

ADULT; AGED; AUSTRIA; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CAUSE OF DEATH; CHOLESTEROL; HUMANS; MALE; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS; SWEDEN; TRIGLYCERIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84924421740     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000174     Document Type: Article

References (39)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-1092.
2. Barnard RJ. Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr. 2007;86:s889-s893.
3. Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006;164:769-774.
4. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164:1094-1102.
5. Engeland A, Tretli S, Bjørge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. BrJ Cancer. 2003;89:1237-1242.
6. Maclnnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17:989-1003.
7. Stocks T, Hergens MP, Englund A, W, Stattin P. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer. 2010;127:1660-1668.
8. Jee SH, Ohrr H, Sull JW, Yun IE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194-202.
9. Häggström C, Stocks T, Ulmert D, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 2012:118: 6199-6206.
10. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
11. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009;20:555-561.
12. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. JNatl Cancer Inst. 2005;97:1428-1437.
13. Hinchliffe SR, Abrams KR, Lambert PC. The impact of under and overrecording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol. 2013;37:11-19.
14. Eloranta S, Adolfsson J, Lambert PC, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24:505-515.
15. Stocks T, Borena W, Strohmaier S, et al. Cohort profile: The Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol. 2010;39:660-667.
16. Eurostat. European Shortlist for Causes of Death. 1998. Available at: http://ec. europa. eu/eurostat/ramon/nomenclatures/index.cfm?TargetUrl=LST-NOM-DTL&StrNom=COD-1998&StrLanguageCode=EN&IntPcKey=&StrLayoutCode=HIERARCHIC. Accessed 1 November 2013.
17. Jonsson H, Holmström B, Duffy SW, Stattin P. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129:1881-1888.
18. Kvåle R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99:1881-1887.
19. Vutuc C, Schernhammer ES, Haidinger G, Waldhor T. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr. 2005;117:457-461.
20. Coviello E. STCOMPADJ: Stata Module to Estimate the Covariateadjusted Cumulative Incidence Function in the Presence of Competing Risks. Statistical Software Components, Boston College Department of Economics. 2009. Available at: http://econpapers.repec.org/RePEc:boc:bocode:s457063. Accessed 17 March 2014.
21. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. 2009;20:1181-1192.
22. Fall K, Garmo H, Gudbjömsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22:1102-1109.
23. Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden-an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol. 2003;37:112-119.
24. Larsen IK, Smástuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218-1231.
25. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140, 000 adults in Austria. Diabetologia. 2006;49:945-952.
26. Frank C, Fallah M, Ji J, Sundquist J, Hemminki K. The population impact of familial cancer, a major cause of cancer. Int J Cancer. 2014;134:1899-1906.
27. Wirén SM, Drevin LI, Carlsson Sy et al. Fatherhood status and risk of prostate cancer: nationwide, population-based case-control study. Int J Cancer. 2013;133:937-943.
28. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011:117: 2086-2095.
29. Discacciati A, Orsini N, Andersson SO, Andrén O, Johansson JE, Wolk A. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer. 2011;105:1061-1068.
30. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.3 (25.04. 2013). Association of the Nordic Cancer Registries. Danish Cancer Society. Available at: http://www-dep. iarc.fr/NORDCAN/SW/frame.asp. Accessed 1 November 2013.
31. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010;58:783-787.
32. Hernán MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology. 2008;19:448-450.
33. Thompson CA, Zhang ZF, Arah OA. Competing risk bias to explain the inverse relationship between smoking and malignant melanoma. Eur J Epidemiol. 2013;28:557-567.
34. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev. 2010;19:2088-2096.
35. Andersen PK, Keiding N. Interpretability and importance of functionals in competing risks and multistate models. StatMed. 2012;31:1074-1088.
36. Karlsen RY Larsen SB, Christensen J, et al. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. Acta Oncol. 2013;52:1609-1614.
37. Perel P, Langenberg C, Ferrie J, Moser K, Brunner E, Marmot M. Household wealth and the metabolic syndrome in the Whitehall II study. Diabetes Care. 2006;29:2694-2700.
38. McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29:29-48.
39. Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and metaanalysis. Int J Epidemiol. 2011;40:804-818.